King’s is arguably the third-oldest university in England, having been founded by King George IV and the Duke of Wellington in 1829, receiving its royal charter in the same year. In 1836 King’s became one of the two founding colleges of the University of London.
King’s is organised into nine academic schools, spread across four Thames-side campuses in central London and another in Denmark Hill in south London. It is one of the largest centres for graduate and post-graduate medical teaching and biomedical research in Europe; it is home to six Medical Research Council centres, the most of any British university, and is a founding member of the King’s Health Partners academic health sciences centre.
King’s has around 25,000 students and 6,113 staff and had a total income of £554.2 million in 2011/12, of which £154.7 million was from research grants and contracts.
King’s College London research articles from Innovation Toronto
- Asthma could be cured within five years after drug breakthrough – April 23, 2015
- Women under-represented in academic medicine – July 12, 2014
- Significant step towards blood test for Alzheimer’s – July 11, 2014
- Cancer breakthrough as scientists discover how cells spread for the first time paving the way for new treatments to halt disease in its tracks – July 8, 2014
- A new use for touchless technology in the operating theatre – June 28, 2014
- Skin layer grown from human stem cells could replace animals in drug and cosmetics testing – April 25, 2014
- Light-activated neurons from stem cells restore function to paralysed muscles
- University of Melboure discovers a cream that could trim fat specifically where it was applied | obesity cream
- ‘Skinsuit’ to help astronauts avoid back problems in space
- VIDEO: Injection-free vaccination
- Genetic Engineers Explain Why Genetically Modified Food Is Dangerous
- Danish scientists ‘close’ to HIV cure
Preventing the transmission of inherited genetic diseases, and increasing food production rates in farmed animals are two potential applications of genome editing technologies that require urgent ethical scrutiny, according to a new report by the Nuffield Council on Bioethics.
The Council, which includes academics from King’s, has today published the first findings of its review looking at the potential impact of recent advances in genome editing such as the CRISPR-Cas9 system across many areas of biological research. The report found evidence that, given its technical advantages and rates of uptake, genome editing is already having an almost unprecedented impact in research. The Council considered the possible effects of these advances in fields such as health care, food production, industry and public health.
Professor Karen Yeung, Director of the Centre for Technology, Law & Society at King’s and a member of the Nuffield Council on Bioethics Working Group, who conducted the review said: ‘We examined the way in which these technologies are being taken up in the research community and what we found is that, because of a number of advantages which they offer in relation to existing techniques for manipulating DNA, they are having an unprecedented transformative effect on the biological sciences and for that reason they have the potential to change our expectations and ambitions about human control over the biological world.
‘One of the reasons why we are undertaking this review is to encourage public deliberation. We think that the potential applications for human health are very important, but also in relation to food production where the technology is really almost ready to go and that is why we are trying to think carefully about the ethical dimensions in order to try and identify the paths of development that we think are the most ethically appropriate.’
The Council will now begin work on two further inquiries addressing the ethical and practical questions raised by possible uses of genome editing in different fields. The first of these will focus on the potential use of genome editing in human reproduction to avoid the transmission of heritable genetic conditions, and the second on livestock to improve systems of animal husbandry and food production.
Dr Andy Greenfield, Chair of the Nuffield Council on Bioethics Working Group who conducted the review, said:‘Genome editing is already showing a potential to transform not only how biological research is carried out, but more importantly our expectations and ambitions for addressing challenges such as disease prevention and food security. Although most uses so far have been in research, the potential applications seem to be almost unlimited, given that the techniques are applicable to all organisms, from bacteria to plants, animals, and human beings.’
Avoiding genetic disease
Human reproductive applications are probably the most talked about potential application of genome editing technologies and raise some of the most complex ethical concerns. Genome editing could one day offer an alternative approach to preventing the inheritance of diseases such as cystic fibrosis.
Concerns have been stirred by reports of research in China to correct disease-causing genetic mutations in non-viable embryos in 2015 and the granting, by the Human Fertilisation and Embryology Authority (HFEA), of a licence to allow genome editing of embryos in the UK February 2016.
Professor Yeung is Chair of the newly established Nuffield Council on Bioethics Working Party on human reproductive applications and said: ‘Genome editing is a potentially powerful set of techniques that holds many future possibilities, including that of altering certain genetic features at the embryonic stage that are known to lead to serious and life-limiting disease. In the UK and in many other countries, a long path to legislative change would have to be followed before this could become a treatment option. But it is only right that we acknowledge where this new science may lead and explore the possible paths ahead to ensure the one on which we set out today is the right one. We will be very interested to hear people’s views on this aspect of genome editing technologies in our new inquiry.’
Many people have concerns about the possible use of genome editing in humans, for example, about the risks of unintended effects due to off target DNA alterations, and the implications of making irreversible changes that will be passed on to future generations. Another key concern is the possible orientation of research towards human enhancement, going beyond disease prevention into the engineering of ‘desirable’ genetic characteristics. As with other technologies and innovations, the potential benefits and harms of genome editing might not be distributed equitably, and some people are worried that negative effects could cause discrimination, injustice or disadvantage to certain individuals or groups.
Learn more: Ethical challenges of genome editing
A new compound developed by University of Bath scientists in collaboration with King’s College London offers unprecedented protection against the harmful effects of UVA radiation in sunlight, which include photo-ageing, cell damage and cancer.
Most sunscreens on the market protect well against solar UVB radiation but have limited effectiveness against UVA-induced damage, relying on the reflective properties of creams to defend against dangerous UVA rays.
However this compound, called the ‘mitoiron claw’ by the team, offers strong protection within our cells precisely where the greatest damage from UVA occurs, and doesn’t interfere with rest of the cell.
The researchers from the Department of Pharmacy and Pharmacology at University of Bath, working with colleagues at Kings College London, hope to see the mitoiron claw compound added to sunscreens and skin care products within 3-4 years.
A breakthrough in cell research may pave the way for treatments which stop cancer spreading through the body.
Scientists at British universities have worked out for the first time how cells are able to migrate from organ to organ.
The new research, spearheaded by biologists at University College London, could transform the way cancer is treated.
Crucially, the discovery has enabled scientists to work out how to block the movement of cells.
It means that aggressive cancer, which can quickly advance away from a primary tumour, might in the future be effectively frozen and isolated as soon as it is detected.